Mitsuko Kondo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mitsuko Kondo has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
Etsuko Tagaya
14 shared publications- Jun Tamaoki
First Department of Medicine, Tokyo Women's Medical University School of Medicine, Japan
10 shared publications Ken Arimura
9 shared publications- Tomohiro Akaba
Department of Respiratory Medicine Tokyo Women's Medical University Tokyo Japan
8 shared publications - Etsuko Tagaya
Department of Respiratory Medicine, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan
7 shared publications - Atsushi Nagai
First Department of Medicine, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
6 shared publications
Latest Publications
- 14 May 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (4)
Impact of varenicline supply suspension on smoking cessation services in Japan's universal health insurance system
- 14 May 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (4)
Impact of varenicline supply suspension on smoking cessation services in Japan's universal health insurance system
- 21 January 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101376
Clinical characteristics and severity of primary ciliary dyskinesia caused by large homozygous deletion including exons 1–4 of DRC1: A multicenter retrospective cohort study
- 21 January 2026
- Published by Elsevier in Respiratory Investigation
- Vol. 64 (2) , 101376
Clinical characteristics and severity of primary ciliary dyskinesia caused by large homozygous deletion including exons 1–4 of DRC1: A multicenter retrospective cohort study
- Open Access
- 1 December 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (12) , e70424
Immunostaining and Ciliary Movement Analysis in Primary Ciliary Dyskinesia With a Homozygous Deletion Involving Exons 1–4 of DRC1 : A Case Report
Primary ciliary dyskinesia (PCD) presents various clinical manifestations, including bronchiectasis, chronic sinusitis, situs inversus, and infertility. PCD is diagnosed through multiple methods, including transmission electron microscopy (TEM), high‐speed video microscopy analysis (HSVA), immunofluorescence (IF), and genetic testing. Recent reports show that a homozygous deletion involving exons 1–4 of DRC1 is common in Japanese patients with PCD. We report the case of a 29‐year‐old male without situs inversus previously diagnosed with diffuse panbronchiolitis, who underwent PCD testing. TEM appeared almost normal, and HSVA showed motile cilia with reduced amplitude. Genetic testing revealed a homozygous deletion involving exons 1–4 of DRC1 . Due to lack of a suitable DRC1 antibody for IF, we used the DRC3 antibody as in previous studies. IF showed the absence of DRC3 in the cilia, suggesting a DRC1 deletion affects DRC3 localization in the cilia. To the best of our knowledge, this case represents one of the earliest reports to perform IF and ciliary movement analysis in PCD with a homozygous deletion involving exons 1–4 of DRC1 .
- 1 December 2025
- Published by Wiley in Respirology Case Reports
- Vol. 13 (12) , e70424
Open AccessImmunostaining and Ciliary Movement Analysis in Primary Ciliary Dyskinesia With a Homozygous Deletion Involving Exons 1–4 of DRC1 : A Case Report
Primary ciliary dyskinesia (PCD) presents various clinical manifestations, including bronchiectasis, chronic sinusitis, situs inversus, and infertility. PCD is diagnosed through multiple methods, including transmission electron microscopy (TEM), high‐speed video microscopy analysis (HSVA), immunofluorescence (IF), and genetic testing. Recent reports show that a homozygous deletion involving exons 1–4 of DRC1 is common in Japanese patients with PCD. We report the case of a 29‐year‐old male without situs inversus previously diagnosed with diffuse panbronchiolitis, who underwent PCD testing. TEM appeared almost normal, and HSVA showed motile cilia with reduced amplitude. Genetic testing revealed a homozygous deletion involving exons 1–4 of DRC1 . Due to lack of a suitable DRC1 antibody for IF, we used the DRC3 antibody as in previous studies. IF showed the absence of DRC3 in the cilia, suggesting a DRC1 deletion affects DRC3 localization in the cilia. To the best of our knowledge, this case represents one of the earliest reports to perform IF and ciliary movement analysis in PCD with a homozygous deletion involving exons 1–4 of DRC1 .
- 30 August 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1066-1069
Nationwide trends in the use of antitussive agents in Japan before, during, and after the COVID-19 Pandemic: A descriptive study using a National Database
- 30 August 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (6) , 1066-1069
Nationwide trends in the use of antitussive agents in Japan before, during, and after the COVID-19 Pandemic: A descriptive study using a National Database
- 26 July 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (5) , 915-917
Nationwide trends in utilization and expenditure of biologic agents approved for asthma in Japan: Insights from the national database (2014–2023)
- 26 July 2025
- Published by Elsevier in Respiratory Investigation
- Vol. 63 (5) , 915-917
Nationwide trends in utilization and expenditure of biologic agents approved for asthma in Japan: Insights from the national database (2014–2023)
- 4 January 2024
- Published by Springer Nature
- p. 25-41
Macrolides and Inflammatory Cells, Signaling, and Mediators
- 4 January 2024
- Published by Springer Nature
- p. 25-41
Macrolides and Inflammatory Cells, Signaling, and Mediators
- Open Access
STING/RANTES Pathway in Airway Epithelium Stimulates Sensitization to Der p1 in an Asthma Model
Background: Asthma development can be attributed to various factors, including viral infections. Several pathogen including viruses activate stimulators of interferon genes (STING), and a small amount of STING agonist functions as adjuvants for sensitization to house dust mite (HDM); however, the associated mechanism is unclear. We investigated the role of STING during sensitization to HDM in airway epithelial cells. Methods: Airway epithelial cell STING expression was analyzed using the GEO database. We delivered cyclic-GMP-AMP (cGAMP), a STING agonist to mice intranasally, and sorted epithelial cells and performed RNA-seq. Human airway epithelial cells (HBEpCs) were stimulated using cGAMP in vitro . Next, we sensitized mice with cGAMP and HDM, Der p1 on Day 1, and challenged with HDM on Day 7, and on Day 8, analyzed cytokine/chemokine levels, bronchoalveolar lavage cell fraction, histology, and the number of group 2 innate lymphoid cells (ILC2s) and dendritic cells (DCs). Furthermore, we evaluated the effect of RANTES/CCL5 alone on sensitizing to HDM. Results: Relative to other pattern recognition receptors, TMEM173 , encoding STING, was highly expressed in HBEpCs, and RANTES expression was remarkably upregulated in cGAMP-treated mice. RANTES , not IL-33 or TSLP , was also activated by cGAMP in HBEpCs, especially in the presence of H 2 O 2 . Type 2 cytokine/chemokine, eosinophil, and goblet cell metaplasia increased with ILC2 and cDC2 accumulation in cGAMP-adjuvanted HDM-sensitized mice. RANTES alone functioned as an adjuvant for induction of type 2 inflammation in mice. Conclusion: STING was highly expressed in airway epithelial cells. STING/RANTES axis may be a crucial pathway for stimulating asthma sensitization.
Open AccessSTING/RANTES Pathway in Airway Epithelium Stimulates Sensitization to Der p1 in an Asthma Model
Background: Asthma development can be attributed to various factors, including viral infections. Several pathogen including viruses activate stimulators of interferon genes (STING), and a small amount of STING agonist functions as adjuvants for sensitization to house dust mite (HDM); however, the associated mechanism is unclear. We investigated the role of STING during sensitization to HDM in airway epithelial cells. Methods: Airway epithelial cell STING expression was analyzed using the GEO database. We delivered cyclic-GMP-AMP (cGAMP), a STING agonist to mice intranasally, and sorted epithelial cells and performed RNA-seq. Human airway epithelial cells (HBEpCs) were stimulated using cGAMP in vitro . Next, we sensitized mice with cGAMP and HDM, Der p1 on Day 1, and challenged with HDM on Day 7, and on Day 8, analyzed cytokine/chemokine levels, bronchoalveolar lavage cell fraction, histology, and the number of group 2 innate lymphoid cells (ILC2s) and dendritic cells (DCs). Furthermore, we evaluated the effect of RANTES/CCL5 alone on sensitizing to HDM. Results: Relative to other pattern recognition receptors, TMEM173 , encoding STING, was highly expressed in HBEpCs, and RANTES expression was remarkably upregulated in cGAMP-treated mice. RANTES , not IL-33 or TSLP , was also activated by cGAMP in HBEpCs, especially in the presence of H 2 O 2 . Type 2 cytokine/chemokine, eosinophil, and goblet cell metaplasia increased with ILC2 and cDC2 accumulation in cGAMP-adjuvanted HDM-sensitized mice. RANTES alone functioned as an adjuvant for induction of type 2 inflammation in mice. Conclusion: STING was highly expressed in airway epithelial cells. STING/RANTES axis may be a crucial pathway for stimulating asthma sensitization.
- Open Access
Serum VEGF Levels on Admission in COVID-19 Patients Correlate with SP-D and Neutrophils, Reflecting Disease Severity: A Prospective Study
Background and objective The COVID-19 pandemic caused by SARS-CoV-2 has resulted in significant global morbidity and mortality. This study aimed to investigate the clinical significance of serum vascular endothelial growth factor (VEGF) in COVID-19 patients and its association with disease severity and pulmonary injury. Methods We prospectively collected data from 71 hospitalized COVID-19 patients between June 2020 and January 2021. Patients were classified as either mild or severe based on their oxygen requirements during hospitalization. Serum VEGF levels were measured using an ELISA kit. Results In comparison to mild cases, significantly elevated serum VEGF levels were observed in severe COVID-19 patients. Furthermore, VEGF levels exhibited a positive correlation with white blood cell count, neutrophil count, and lymphocyte count. Notably, serum surfactant protein-D (SP-D), an indicator of alveolar epithelial cell damage, was significantly higher in patients with elevated VEGF levels. Conclusion These results suggest that elevated serum VEGF levels could serve as a prognostic biomarker for COVID-19 as it is indicative of alveolar epithelial cell injury caused by SARS-CoV-2 infection. Additionally, we observed a correlation between VEGF and neutrophil activation, which plays a role in the immune response during endothelial cell injury, indicating a potential involvement of angiogenesis in disease progression. Further research is needed to elucidate the underlying mechanisms of VEGF elevation in COVID-19.
Open AccessSerum VEGF Levels on Admission in COVID-19 Patients Correlate with SP-D and Neutrophils, Reflecting Disease Severity: A Prospective Study
Background and objective The COVID-19 pandemic caused by SARS-CoV-2 has resulted in significant global morbidity and mortality. This study aimed to investigate the clinical significance of serum vascular endothelial growth factor (VEGF) in COVID-19 patients and its association with disease severity and pulmonary injury. Methods We prospectively collected data from 71 hospitalized COVID-19 patients between June 2020 and January 2021. Patients were classified as either mild or severe based on their oxygen requirements during hospitalization. Serum VEGF levels were measured using an ELISA kit. Results In comparison to mild cases, significantly elevated serum VEGF levels were observed in severe COVID-19 patients. Furthermore, VEGF levels exhibited a positive correlation with white blood cell count, neutrophil count, and lymphocyte count. Notably, serum surfactant protein-D (SP-D), an indicator of alveolar epithelial cell damage, was significantly higher in patients with elevated VEGF levels. Conclusion These results suggest that elevated serum VEGF levels could serve as a prognostic biomarker for COVID-19 as it is indicative of alveolar epithelial cell injury caused by SARS-CoV-2 infection. Additionally, we observed a correlation between VEGF and neutrophil activation, which plays a role in the immune response during endothelial cell injury, indicating a potential involvement of angiogenesis in disease progression. Further research is needed to elucidate the underlying mechanisms of VEGF elevation in COVID-19.
- Open Access
- 1 April 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (2) , 248-257
Analysis of the clinical features of Japanese patients with primary ciliary dyskinesia
- 1 April 2022
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (2) , 248-257
Open AccessAnalysis of the clinical features of Japanese patients with primary ciliary dyskinesia